<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02900235</url>
  </required_header>
  <id_info>
    <org_study_id>MT-3995-E11</org_study_id>
    <nct_id>NCT02900235</nct_id>
  </id_info>
  <brief_title>Mass Balance Study of MT-3995</brief_title>
  <official_title>An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]-MT-3995 After a Single Oral Dose to Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitsubishi Tanabe Pharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mitsubishi Tanabe Pharma Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the absorption, metabolism and excretion of
      MT-3995 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total radioactivity in urine and faeces</measure>
    <time_frame>up to 99 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed plasma concentration [Cmax]</measure>
    <time_frame>up to 99 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time at which Cmax occurs [tmax]</measure>
    <time_frame>up to 99 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to the last measurable concentration [AUC0-t]</measure>
    <time_frame>up to 99 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity [AUC0-∞]</measure>
    <time_frame>up to 99 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life [t1/2]</measure>
    <time_frame>up to 99 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal elimination rate constant [Kel]</measure>
    <time_frame>up to 99 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by adverse events (AEs)</measure>
    <time_frame>up to 99 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability as measured by vital signs</measure>
    <time_frame>up to 99 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>MT-3995</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[14C]-MT-3995 after a single oral dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MT-3995</intervention_name>
    <arm_group_label>MT-3995</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide written informed consent to participate in the study

          -  Caucasian male aged at least 35 years at Screening

          -  Healthy and free from clinically significant illness or disease at Screening and Day-1

          -  A body weight of 60 to 110 kg at Screening and Day-1

          -  Vital signs within the following ranges at Screening, Day-1 and Pre-dose:

               -  Body temperature : 35.0°C to 37.5°C

               -  Systolic blood pressure: 90 to 140 mmHg

               -  Diastolic blood pressure: 50 to 90 mmHg

          -  Regular daily bowel movements

        Exclusion Criteria:

          -  Presence or history of severe adverse reaction or allergy to any medicinal product

          -  Participation in more than three clinical studies of an Investigational Medicinal
             Product (IMP) in the previous year or participated in a clinical study of any IMP
             within 12 weeks or five half-lives

          -  Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism or excretion of drugs or which may jeopardise the subject in
             case of participation in the study. The Investigator should be guided by evidence of
             any of the following:

               -  History of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or
                  rectal bleeding considered clinically significant by the Investigator

               -  History of major gastrointestinal tract surgery such as gastrectomy,
                  gastroenterostomy or bowel resection

               -  History or clinical evidence of pancreatic injury or pancreatitis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Mitsubishi Tanabe Pharma Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational center</name>
      <address>
        <city>City name</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2016</study_first_submitted>
  <study_first_submitted_qc>September 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 14, 2016</study_first_posted>
  <last_update_submitted>January 29, 2017</last_update_submitted>
  <last_update_submitted_qc>January 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

